Immune therapy and targeted therapy in urothelial cancer

Poster Session 73

Location: Room Amsterdam, North Hall (Level 1)

Chairs: Y. Allory, Creteil (FR)
A. Sato, Tokorozawa (JP)
A. Vlahou, Athens (GR)

Aims and objectives of this session
Not all patients respond to BCG therapy for urothelium tumours. Immunological mechanisms relevant to a possible improvement of BCG treatment will be discussed in this session. In addition, novel functions of growth factors which are highly expressed in bladder cancer will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

964

Immune responsiveness to tuberculin in vitro may predict clinical outcome of intravesical BCG immunotherapy in bladder cancer
By: Jallad S.1, Thomas D.2, Thomas P.3, Newport M.4, Kern F.4
Institutes: 1Brighton and Sussex Medical School, Dept. of Urology, Brighton, United Kingdom, 2Brighton and Sussex Medical School, Division of Medicine, Brighton, United Kingdom, 3Brighton and Sussex University Hospitals, Dept. of Urology, Brighton, United Kingdom, 4Brighton and Sussex University Hospitals, Division of Medicine, Brighton, United Kingdom

965

Institutes: Nara Medical University, Dept. of Urology, Kashihara, Japan

966

Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells
By: Ferreira-Teixeira M.1, Parada B.1, Paiva-Oliveira D.2, Alves V.3, Sousa V.4, Chijioke O.5, Münz C.5, Reis F.6, Rodrigues-Santos P.7, Gomes C.6
Institutes: 1Coimbra University Hospital (CHUC), Urology and Renal Transplantation, Coimbra, Portugal, 2University of Coimbra - Faculty of Medicine, Institute For Biomedical Imaging and Life Sciences (IBILI), Coimbra, Portugal, 3University of Coimbra - Faculty of Medicine, Institute of Immunology, Coimbra, Portugal, 4University of Coimbra - Faculty of Medicine, Institute of Anatomical and Molecular Pathology, Coimbra, Portugal, 5University of Zurich, Viral Immunobiology, Institute of Experimental Immunology, Zurich, Switzerland, 6University of Coimbra - Faculty of Medicine, Laboratory of Pharmacology and Experimental Therapeutics, Institute For Biomedical Imaging and Life Sciences (IBILI), Coimbra, Portugal, 7University of Coimbra - Center For Neurosciences and Cell Biology (CNC), Immunology and Oncology Laboratory, Coimbra, Portugal

968

IFN alpha modulates the response to BCG immunotherapy in bladder cancer patients with specific CTLA4 and CD28 single nucleotide polymorphisms
By: Eguwarathan K., Rahmat J., Tham S.M., Lim Y.K., Sng J.H., Raman L., Ma Z.M., Chan Y.H., Tsang W.C., Chiong E., Mahendran R.
Institutes: National University Singapore, Dept of Urology, Singapore, Singapore
Poster Session 73

969 Inhibition of LIM-SH3 domain protein 1 (LASP1) augments the anti-cancer effect of cisplatin in bladder cancer
By: Dejima T.¹, Takeuchi A.¹, Shiota M.¹, Black P.², Eto M.¹, Naito S.¹, Gleave M.², Ong C.²
Institutes: ¹Kyusyu University, Dept. of Urology, Fukuoka, Japan, ²The Vancouver Prostate Centre, Dept. of Urologic Sciences, University of British Columbia, Vancouver, Canada

970 HGF-MET-MMP and VEGF-C signaling as a potential target for invasive bladder cancer therapy
By: Shintani T., Daizumoto K., Fukawa T., Nakatsuji H., Fukumori T., Takahashi M., Kanayama H.
Institutes: Institute of Biomedical Sciences, Tokushima University Graduate School, Dept. of Urology, Tokushima, Japan

971 The novel checkpoint kinase 1 inhibitor MK-8776 strongly sensitizes bladder cancer cells to gemcitabine
By: Isono M.¹, Sato A.¹, Asano T.¹, Okubo K.¹, Hoffmann M.², Schulz W.², Asano T.¹
Institutes: ¹National Defense Medical College, Dept. of Urology, Tokorozawa, Japan, ²Heinrich Heine University, Dept. of Urology, Düsseldorf, Germany

972 T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+
By: Hayashi T.¹, Oo H.², Jäger W.², Kobatake K.¹, Goriki A.², Seiler R.², Todenhöfer T.², Li N.², Fazli L.², Matsubara A.¹, Black P.²
Institutes: Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

973 Pathological significance and prognostic roles of c-Fes expression in bladder cancer differ depending on the grade
By: Asai A., Miyata Y., Yasuda T., Nakamura Y., Matsuo T., Ohba K., Sakai H.
Institutes: Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan

974 Reduced expressions of 4N1K-peptide derived from thrombospondin-2 is associated with malignant aggressiveness and prognosis in bladder cancer
By: Mochizuki Y.¹, Miyata Y.¹, Yasuda T.¹, Nakamura Y.¹, Matsuo T.¹, Ohba K.¹, Furusato B.², Fukuoka J.³, Sakai H.¹
Institutes: Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, ³Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan

975 Compound A inhibits urothelial tumorigenesis via both glucocorticoid receptor and androgen receptor pathways
By: Ide H.², Inoue S.³, Zheng Y.², Kashiwagi E.⁴, Kawahara T.⁵, Miyamoto H.¹
Institutes: ¹University of Rochester, Dept. of Pathology, Urology and Oncology, Rochester, United States of America, ²Johns Hopkins University, Dept. of Pathology and Urology, Baltimore, United States of America, ³University of Rochester, Dept. of Pathology and Oncology, Rochester, United States of America, ⁴Kyushu University, Dept. of Urology, Fukuoka, Japan, ⁵Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan

15:13 - 15:20 New targets in urothelial cancer
Y. Allory, Creteil (FR)